Pharmacokinetic Bioequivalence, Safety, and Immunogenicity of DMB-3111, a Trastuzumab Biosimilar, and Trastuzumab in Healthy Japanese Adult Males: Results of a Randomized Trial

BACKGROUND: DMB-3111 is a biosimilar trastuzumab drug being jointly developed by Meiji Seika Pharma (Japan) and Dong-A Socio Holdings (Korea). We investigated the bioequivalence of DMB-3111 relative to trastuzumab. OBJECTIVES: The aim of this study was to investigate the bioequivalence between DMB-3...

Descripción completa

Detalles Bibliográficos
Autores principales: Morita, Jun, Tanaka, Masashi, Nomoto, Masahiro, Matsuki, Shunji, Tsuru, Tomomi, Matsuguma, Kyoko, Shiramoto, Masanari
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2015
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4746214/
https://www.ncbi.nlm.nih.gov/pubmed/26691837
http://dx.doi.org/10.1007/s40259-015-0153-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4746214/
https://www.ncbi.nlm.nih.gov/pubmed/26691837
http://dx.doi.org/10.1007/s40259-015-0153-2

Ejemplares similares